Type I and II Endometrial Cancers: Have They Different Risk Factors?Veronica Wendy Setiawan, Jennifer A. Doherty, Alicja Wolk et al.|Journal of Clinical Oncology|2013Cited by 833
Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406)Scott Kopetz, Howard S. Höchster, Katherine A. Guthrie et al.|Journal of Clinical Oncology|2020Cited by 391
Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast CancerDouglas Yee, Minetta C. Liu, Angela DeMichele et al.|JAMA Oncology|2020Cited by 225